Literature DB >> 7910754

Effects of medication history on midlatency auditory evoked responses in schizophrenia.

R J Erwin1, D Shtasel, R E Gur.   

Abstract

The recovery cycle of the P1 component of the auditory evoked potential (50-70 ms latency) has been reported as abnormal in both unmedicated and medicated patients with schizophrenia when a paired stimuli protocol is used to examine recovery. However, findings have been mixed when a stimulus train protocol is used. This study examined the effects of medication history on P1 abnormalities in schizophrenia assessed by a stimulus train protocol. Auditory evoked potentials were recorded from 14 normal controls, 14 neuroleptic naive patients with schizophrenia and 14 previously medicated patients in response to binaural clicks presented at three stimulus rates: 1/s, 5/s and 10/s. Neuroleptic naive patients showed a smaller P1 at the baseline rate (1/s) and greater recovery (less amplitude suppression) at faster rates than did normal controls or previously medicated patients. Additional analyses suggested that this latter effect was not due to smaller baseline P1 amplitudes. Greater recovery in neuroleptic naive patients was not associated with clinical symptomatology contrary to previous findings of the authors for a mixed sample of neuroleptic naive and previously medicated patients. Medication status appears to account for some of the variability in P1 abnormalities in schizophrenia although identification of the underlying mechanism responsible requires further study.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910754     DOI: 10.1016/0920-9964(94)90019-1

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  The auditory P50 component to onset and offset of sound.

Authors:  Hillel Pratt; Arnold Starr; Henry J Michalewski; Naomi Bleich; Nomi Mittelman
Journal:  Clin Neurophysiol       Date:  2007-12-04       Impact factor: 3.708

2.  Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.

Authors:  Jie Zhang; Chadi G Abdallah; Junqing Wang; Xiaona Wan; Chunlian Liang; Liyun Jiang; Yuzhen Liu; Haixing Huang; Xiaohong Hong; Qingjun Huang; Renhua Wu; Chongtao Xu
Journal:  Psychiatry Res       Date:  2012-06-16       Impact factor: 3.222

3.  A putative electrophysiological biomarker of auditory sensory memory encoding is sensitive to pharmacological alterations of excitatory/inhibitory balance in male macaque monkeys.

Authors:  William B Holliday; Kate Gurnsey; Robert A Sweet; Tobias Teichert
Journal:  J Psychiatry Neurosci       Date:  2018-05       Impact factor: 6.186

4.  Noradrenergic antagonism of the P13 and N40 components of the rat auditory evoked potential.

Authors:  Sarah K Keedy; Megan Marlow-O'Connor; Beth Beenken; Jill Dorflinger; Marc Abel; Roland J Erwin
Journal:  Psychopharmacology (Berl)       Date:  2006-11-10       Impact factor: 4.530

5.  Loudness- and time-dependence of auditory evoked potentials is blunted by the NMDA channel blocker MK-801.

Authors:  Tobias Teichert
Journal:  Psychiatry Res       Date:  2017-06-15       Impact factor: 3.222

6.  Auditory processing in schizophrenia during the middle latency period (10-50 ms): high-density electrical mapping and source analysis reveal subcortical antecedents to early cortical deficits.

Authors:  Victoria M Leavitt; Sophie Molholm; Walter Ritter; Marina Shpaner; John J Foxe
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

7.  Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate.

Authors:  Stephan Bickel; Daniel C Javitt
Journal:  Behav Brain Res       Date:  2009-05-09       Impact factor: 3.332

8.  Deficit Effect Sizes and Correlations of Auditory Event-Related Potentials at First Hospitalization in the Schizophrenia Spectrum.

Authors:  Dean F Salisbury; Justine Kohler; Martha E Shenton; Robert W McCarley
Journal:  Clin EEG Neurosci       Date:  2019-08-07       Impact factor: 2.046

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.